MIA Co-Medical Directors join Riverina Melanoma Ride
Prof Georgina Long and Prof Richard Scolyer, cycled from Albury to Wagga on Day 1 of Riverina Melanoma Ride.
Why we all need to take steps for Melanoma March
Melanoma March 2022 is aiming to raise $1 million for a world-first clinical trial of a Personalised Immunotherapy Platform which could transform melanoma treatment.
State of the Nation – A Report into Melanoma
A landmark report provides status of melanoma in Australia, and the the roadmap to achieve zero deaths from melanoma this decade.
Neoadjuvant therapy, a breakthrough in Stage III melanoma treatment
In what is being hailed as one of the biggest breakthroughs in melanoma treatment since the advent of immunotherapy, a new study has revealed that drug treatment before surgery is effective in preventing deadly spread of the disease.
MIA joins Sydney Health Partners
MIA has joined Sydney Health Partners, with a shared focus on more rapidly translating research evidence into patient benefit.
Olympians join forces for melanoma warning
Jana Pittman and Melinda Gainsford-Taylor back our Game On Mole campaign, in support of their much loved coach.
Prof Scolyer receives UTAS Alumni Award
The 'Distinguished Alumni Award' from University of Tasmania honours the exceptional impact of his work around the world.
Medical Directors receive USYD VC’s Award
The 'Outstanding Research Award' recognises their life-saving discoveries transforming melanoma patient care.
MIA researchers on Highly Cited 2021 List
The highly anticipated annual list is the “who’s who” of the scientific elite from across the globe.
A paradigm shift in melanoma treatment
Drug therapy looks set to become the standard treatment for high-risk early stage melanoma patients.